
AMR: ENABLE selects Mutabilis candidate
Efficacy of beta-lactam antibiotics, which represent 65% of the antibiotics sold throughout the world, is increasingly challenged in Gram-negative...

ADC Therapeutics set to go public
The number of shares to be offered and the price range for the proposed offering have still to be determined. Despite an internal review conducted...

Tecentriq-Avastin combo hits endpoint in liver cancer
Data from 501 treatment-native HCC patients enrolled in the open label IMbrave150 Phase III study demonstrated a incremental improvement...

EMA greenlights new medicines
With the three innovative medicines and four generics the number of recommended medicines raised to 47 in 2019. The Committee saw a positive...

UniQure looking to raise US$200m
The Amsterdam-based company announced that it had commenced an underwritten public offering of US$200m of its ordinary shares. uniQure also intends...

Abcam buys Expedeon’s immunology business
“This purchase price is equivalent to twice Expedeon’s current market capitalisation or excess of 9-times 2018 annual group revenue,” the company...

Vaximm goes East for cancer vaccine deal
T-cell immunotherapy expert Vaximm plans to use Artificial Intelligence (AI) to develop personalised cancer vaccines. The biotech is collaboration...